Update on gemcitabine/carboplatin in patients with advanced non-small cell lung cancer

Seminars in Oncology

Volumn 30, Issue 4 SUPPL. 10, 2003, Pages 2-12

  Harper, Peter ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETABOLITE; CARBOPLATIN; CISPLATIN; GEMCITABINE; IFOSFAMIDE; MITOMYCIN;

ADVANCED CANCER; AGE; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BLEEDING; BLOOD TOXICITY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0041965974     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(03)00279-3     Document Type: Conference Paper

References (55)

1. American Cancer Society: Cancer Facts and Figures 2002. Atlanta, GA, American Cancer Society, 2002, p 11
2. Page N, Read W, Tierney M, et al: The epidemiology of small cell lung cancer. Proc Am Soc Clin Oncol 21:305a, 2002 (abstr 1216)
3. Gridelli C, Perrone F, Monfardini S: Lung cancer in the elderly. Eur J Cancer 33:2313-2314, 1997
4. Havlik RJ, Yancik R, Long S, et al: The National Cancer Institute on Aging and the National Cancer Institute SEER Collaborative study on comorbidity and early diagnosis of cancer in the elderly. Proc Am Soc Clin Oncol 20:322a, 2001 (abstr 1285)
5. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311:899-909, 1995
6. Stephens R, Fairlamb D, Gower N, et al: The Big Lung Trial (BLT): Determining the value of cisplatin-based chemotherapy for all patients with NSCLC. Preliminary results in the supportive care setting. Proc Am Soc Clin Oncol 21:291a, 2002 (abstr 1161)
7. Cullen MH, Billingham LJ, Woodroffe CM, et al: Mitomycin, ifosfamide, and cisplatin in unresectable non-small cell lung cancer: A randomized trial. Ann Oncol 17:3188-3194, 1999
8. Crino L, Cappuzzo F: Present and future treatment of advanced non-small cell lung cancer. Semin Oncol 29:9-16, 2002 (suppl 9)
9. Cardenal F, Lopez-Cabrerizo M, Anton A, et al: Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 17:12-18, 1999
10. Crino L, Scagliotti GV, Ricci S, et al: Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 17: 3522-3530, 1999
11. Sandler AB, Nemunaitis J, Denham C, et al: Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-smatt cell lung cancer. J Clin Oncol 18:122-130, 2000
12. Abratt RP, Bezwoda WR, Falkson G, et al: Efficacy and safety profile of gemcitabine in non-small cell lung cancer: A phase II study. J Clin Oncol 12:1535-1540, 1994
13. Anderson H, Lund B, Bach F, et al: Single-agent activity of weekly gemcitabine in advanced non-small celt lung cancer: A multicenter extended phase II study. Eur J Cancer 32A:243-248, 1996
14. Gatzemeier U, Shepherd F, LeChevalier T, et al: Activity of gemcitabine in patients with non-small cell lung cancer: A multicenter, extended phase II study. Eur J Cancer 32A:243-248, 1996
15. Anderson H, Hopwood P, Stephens RJ, et al: Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small celt lung cancer - A randomized trial with quality of life as the primary outcome. Br J Cancer 83:447-453, 2000
16. Perng RP, Chen YM, Ming-Liu J, et al: Gemcitabine vs the combination of cisplatin and etoposide in patients with inoperable non-small cell lung cancer in a phase II randomized study. J Clin Oncol 15:2097-2102, 1997
17. ten Bokkel Huinink WW, Bergman B, Chemaissani A, et al: Single-agent gemcitabine: An active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer. Lung Cancer 26:85-94, 1999
18. Shepherd FA, Abratt RP, Anderson H, et al: Gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer. Semin Oncol 24:50-55, 1997 (suppl 7)
19. Edelman MJ, Quam H, Mullins B: Interactions of gemcitabine, carboplatin, and paclitaxel in molecularly defined non-small cell lung cancer cell lines. Cancer Chemother Pharmacol 48:141-144, 2001
20. Peters GJ, Bergman AM, Ruiz van Haperen VWT, et al: Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22:72-79, 1995
21. Fram RJ, Cusik PS, Marinos MG: Studies on mutagenesis and repair induced by platinum analogs. Mutat Res 173: 13-18, 1986
22. Albain KS, Crowley JJ, LeBlanc M, et al: Survival determinants in extensive-stage non-small cell lung cancer: The Southwest Oncology Group experience. J Clin Oncol 9:1618-1626, 1991
23. Sandler A, Nemunaitis J, Dehnam C, et al: Phase III study of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 18:122-130, 2000
24. Cardenal F, Lopez-Cabrerizo MP, Anton A, et al: Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 17:12-18, 1999
25. Steward WP, Dunlop DJ, Dabouis G, et al: Phase I/II study of gemcitabine and cisplatin in non-small cell lung cancer: Preliminary results. Semin Oncol 5:43-47, 1996 (suppl 10)
26. Crino L, Scagliotti G, Marangolo M, et al: Cisplatin-gemcitabine combination in advanced non-small cell lung cancer: Preliminary results. Semin Oncol 15:297-303, 1997
27. Sandler A, Crino L, Steward WP, et al: Extended survival in stage III and IV non-small cell lung cancer (NSCLC) patients treated with gemcitabine plus monthly cisplatin. Proceedings of the 21st European Society of Medical Oncology. Ann Oncol 7:91a, 1996 (suppl 5)
28. Abratt RP, Bezwoda WR, Goedhals L, et al: Weekly gemcitabine with monthly cisplatin: Effective chemotherapy for advanced non-small cell lung cancer. J Clin Oncol 15:744-749, 1997
29. Anton A, Carrato A, Gonzalez-Larriba JL, et at: Phase II activity of gemcitabine in combination with cisplatin in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 15:380a, 1996 (abstr 1134)
30. Bonomi PD, Finkelstein DM, Ruckdeschel JC, et al: Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV NSCLC: A study of the Eastern Cooperative Oncology Group. J Clin Oncol 7:1602-1613, 1989
31. Green MR, Kreisman H, Lickart S, et al: Carboplatin in non-small cell lung cancers: The Cancer and Leukemia Group B experience. Carboplatin (JM-9), in Bunn PA Jr, Canetta R, Ozols R, et al (eds): Current Perspectives and Future Directions. Philadelphia, PA, Saunders, 1990, pp 301-306
32. Klastersky J, Sculier JP, Lacroix A, et al: A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small cell lung cancer: European Organization of Research and Treatment of Cancer Protocol 07861. J Clin Oncol 8:1556-1562, 1989
33. Heching NI, Lotan C, Kaduri L, et al: Gemcitabine and carboplatinum in advanced non-small cell lung carcinoma: Results of a single institution phase II study. Proc Am Soc Clin Oncol 18:508a, 1999 (abstr 1959)
34. Carrato A, Garcia-Gomez J, Alberola V, et al: Carboplatin in combination with gemcitabine in advanced non-small cell lung cancer: Comparison of trials using different schedules. Proc Am Soc Clin Oncol 18:498a, 1999 (abstr 1922)
35. Ng EW, Sandler AB, Einhorn LH, et al: A phase II study of carboplatin plus gemcitabine in non small cell lung cancer. (NSCLC). Proc Am Soc Clin Oncol 17:468, 1998 (abstr 1801)
36. Masotti A, Morandini G: Phase II trial of gemcitabine and carboplatin in advanced non-small cell lung cancers. Proc Am Soc Clin Oncol 18:517a, 1999 (abstr 1992)
37. Jovtis S, Brocato N, Temperley G, et al: Final results of a phase II trial of first-line therapy with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 29:46, 2000 (suppl 1) (abstr 150)
38. Carmichael J, Allerheiligen S, Walling J: A phase I study of gemcitabine and carboplatin in non-small cell lung cancer. Semin Oncol 23:55-59, 1996 (suppl 10)
39. Parente B, Barroso A, Conde S, et al: A randomized phase III study of gemcitabine and carboplatinum versus vinorelbine and carboplatinum in advanced non-small cell lung cancer. Lung Cancer 29:69, 2000 (suppl 1) (abstr 197)
40. Danson S, Clemons M, Middleton M, et al: A randomized study of gemcitabine with carboplatin (GC) versus mitomycin C, ifosfamide, and cisplatin (MIC) as first line chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 20:322a, 2001 (abstr 1285)
41. Iaffaioli RV, Tortoriello A, Facchini G, et al: Phase I-II study of gemcitabine and carboplatin in stage III-IV non-small cell lung cancer. J Clin Oncol 17:921-926, 1999
42. Sederholm C: A phase II study of gemcitabine plus carboplatin in chemonaive patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 18:490a, 1999 (abstr 1889)
43. Edelman MJ, Gandara DR, Lau D, et al: Sequential chemotherapy in non-small cell lung cancer (NSCLC): Carboplatin and gemcitabine followed by paclitaxel. Proc Am Soc Clin Oncol 19:525a, 2000 (abstr 2063)
44. Domine M, Casado V, Estevez LG, et al: Carboplatin and gemcitabine in advanced non-small cell lung cancer: An effective and well tolerated regimen. Lung Cancer 29:85a, 2000 (suppl 1) (abstr 281)
45. Mazzanti P, Massacesi C, Mattioli R, et al: Gemcitabine-cisplatin (GP) vs. gemcitabine-carboplatin (GC) in advanced non-small cell lung cancer (NSCLC): A multicenter phase II randomized trial. Eur J Cancer 37:550, 2001 (suppl 6) (abstr 172)
46. Murad A, Guimares RC, Aranao BC, et al: Phase Il trial of the use of carboplatin and gemcitabine (G) in the treatment of advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 21:228b, 2002 (abstr 2729)
47. Maestu IC, Torregrosa D, Llorca C, et al: Efficacy of carboplatin and gemcitabine in the treatment of elderly patients with advanced non small cell lung cancer (ANSCLC). Proc Am Soc Clin Oncol 20:401a, 2001 (abstr 1599)
48. Carrato A, Alberola V, Massuti B, et al: Combination of gemcitabine and carboplatin as first-line treatment in non-small cell lung cancer. Ann Oncol 9:89, 1998 (abstr 431P)
49. LeChevalier T, Brisgand D, Douillard JY, et al: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: Results of a European multicenter trial including 312 patients. J Clin Oncol 12:360-367, 1994
50. Kelly K, Crowley J, Bunn PA, et al: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 19:3210-3218, 2001
51. Sederholm C: Gemcitabine compared with gemcitabine plus carboplatin in advanced NSCLC: A phase III study by the Swedish Lung Cancer Study Group. Proc Am Soc Clin Oncol 21:291a, 2002 (abstr 1162)
52. Zatloukal P, Novakova L, Petruzelka L, et al: Gemcitabine plus cisplatin (GCis) versus gemcitabine plus carboplatin (GCarb) in patients with stage IIIB and IV non-small lung cancer (NSCLC): Final results of Czech Lung Cancer Cooperative Group phase III randomized trial. Proc Am Soc Clin Oncol 21:307a, 2002 (abstr 1225)
53. Rudd R, Gower N, James L, et al: Phase III randomized comparison of gemcitabine and carboplatin with mitomycin, ifosfamide and cisplatin in advanced NSCLC. Proc Am Soc Clin Oncol 21:292a, 2002 (abstr 1164)
54. Alberola V, Camps C, Provencia M, et al: Cisplatin-gemcitabine (CG) versus cisplatin-gemcitabine/vinorelbine (CGV) versus sequential doublets of gemcitabine/vinorelbine followed by ifosfamide/vinorelbine (GV/IV) in advanced non-small cell lung cancer (NSCLC): Results of a Spanish Lung Cancer Group phase III trial (GEPC/98-02). Proc Am Soc Clin Oncol 20:308a, 2001 (abstr 1229)
55. Thomas P, Robinet G, Ferri-Dessens RM, et al: Phase I trial of gemcitabine and carboplatin in metastatic non-small cell lung cancer: A Groupe Franĉais de Pneumo-Cancérologie study. Lung Cancer 36:191-198, 2002